The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.

Neuropsychopharmacology · 2023 · PMC10018616 · PMID 36928351

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Discussion Although it showed a trend to enhance but had no statistically significant effect on the primary endpoint, EBC, luvadaxistat significantly improved MMN and showed a trend toward improving ASSR, in both cases at 50 mg, but not with 500 mg.

also in 53,322 other papers

a statistical trendno p-value reported

nominally significantno p-value reported

We observed a nominally significant improvement in mismatch negativity (MMN) and a statistical trend to improvement for auditory steady-state response at 40 Hz, in both cases with 50 mg, but not with 500 mg, compared with placebo.

also in 2,798 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.